Stockscreener 앱 받기
1.1901
0.42%
-0.0099
전일 마감가:
$1.20
열려 있는:
$1.2
하루 거래량:
47,965
Relative Volume:
0.10
시가총액:
$2.73M
수익:
$35.75M
순이익/손실:
$11.57M
주가수익비율:
-0.3126
EPS:
-3.8069
순현금흐름:
$-26.25M
1주 성능:
-26.69%
1개월 성능:
-41.13%
6개월 성능:
-79.47%
1년 성능:
-92.51%
1일 변동 폭
$1.18
$1.23
1주일 범위
$1.1758
$1.72
52주 변동 폭
$1.1758
$15.33
레드힐 바이오파마 ADR Stock (RDHL) Company Profile
명칭
Redhill Biopharma Ltd Adr
전화
-
주소
-
RDHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.1901 | 2.75M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
151.33 | 65.61B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 44.72B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.465 | 43.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.61 | 17.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.75 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
레드힐 바이오파마 ADR Stock (RDHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-08-31 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2020-09-11 | 개시 | BTIG Research | Buy |
| 2019-07-12 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 개시 | Nomura | Buy |
| 2017-10-06 | 개시 | Seaport Global Securities | Buy |
| 2017-10-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-24 | 재확인 | FBR & Co. | Outperform |
| 2016-07-27 | 재확인 | FBR Capital | Outperform |
| 2015-09-29 | 개시 | Nomura | Buy |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2015-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-15 | 재확인 | ROTH Capital | Buy |
모두보기
레드힐 바이오파마 ADR 주식(RDHL)의 최신 뉴스
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
RedHill wins $8 million judgment in New York court - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
Cathie Wood Predictions 2022 - New Trader U
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
레드힐 바이오파마 ADR (RDHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
1.04%
자본화:
|
볼륨(24시간):